Chinese firms that supplied raw materials for over a billion doses of weight-loss drugs in the US are now pivoting to generics, Reuters reported. With the FDA restricting compounded copies of Novo Nordisk's Wegovy and Eli Lilly's Zepbound, companies like Sinopep and Hybio are targeting markets such as Canada and Brazil, where key patents expire in 2026.